Identification of the target for therapeutic recombinant anti-apoB100 peptide antibodies in human atherosclerotic lesions

Goncalves et al, 2009, Atherosclerosis Journal, Volume 205, ISSUE 1, P96-100, July 01, 2009

Accumulation of oxidized LDL in the arterial wall is believed to play a key role in the development of atherosclerosis. Experimental studies have identified the presence of immune responses against epitopes in oxidized LDL that protects against atherosclerosis. We have produced human recombinant IgG against one of these epitopes (aldehyde-modified apoB-100 amino acids 661–680) and demonstrated that treatment with this human IgG1 2D03 antibody markedly reduces atherosclerosis in hypercholesterolemic mice.